Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy

BACKGROUND: The objective of this study was to identify serum biomarkers capable of predicting clinical outcomes in previously-treated NSCLC patients with wild-type for EGFR activating mutations or insufficient tissue for mutation status determination. METHODS: Sixty-six Luminex immunoassays represe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Fidler, Mary Jo, Frankenberger, Casey, Seto, Richard, Lobato, Gabriela C, Fhied, Cristina L, Sayidine, Selina, Basu, Sanjib, Pool, Mark, Karmali, Reem, Batus, Marta, Lie, Wen-Rong, Hayes, David, Mistry, Jehangir, Bonomi, Philip, Borgia, Jeffrey A
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601637/
https://ncbi.nlm.nih.gov/pubmed/28938541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17510
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares